Pfizer-BioNTech vaccine deliveries could start 'before Christmas'
(Reuters) - Pfizer Inc PFE.N and BioNTech 22UAy.DE could secure emergency U.S.
and European authorization for their COVID-19 vaccine next month after final trial
results showed it had a 95% success rate and no serious side effects, the
drugmakers said on Wednesday. “Today is a special day.”
Pfizer завершила испытания вакцины от COVID-19, сообщила о 95-процентной эффективности.
Ждём Владимира Владимировича...на бис прям ждём...
(Reuters) - Pfizer Inc PFE.N and BioNTech 22UAy.DE could secure emergency U.S.
and European authorization for their COVID-19 vaccine next month after final trial
results showed it had a 95% success rate and no serious side effects, the
drugmakers said on Wednesday. “Today is a special day.”
Pfizer завершила испытания вакцины от COVID-19, сообщила о 95-процентной эффективности.
Ждём Владимира Владимировича...на бис прям ждём...